Previous Article | Next Article 
Journal of Bacteriology, August 2001, p. 4761-4770, Vol. 183, No. 16
0021-9193/01/$04.00+0 DOI: 10.1128/JB.183.16.4761-4770.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Domain Interactions in the Yeast ATP Binding Cassette Transporter
Ycf1p: Intragenic Suppressor Analysis of Mutations in the
Nucleotide Binding Domains
Juan M.
Falcón-Pérez,1
Mónica
Martínez-Burgos,1
Jesús
Molano,2
María J.
Mazón,1 and
Pilar
Eraso1,*
Instituto de Investigaciones Biomédicas
"Alberto Sols," CSIC-UAM,1 and
Unidad de Genética Molecular, Servicio de
Bioquímica, Hospital La Paz,2 Madrid,
Spain
Received 8 February 2001/Accepted 24 May 2001
 |
ABSTRACT |
The yeast cadmium factor (Ycf1p) is a vacuolar ATP binding cassette
(ABC) transporter required for heavy metal and drug detoxification. Cluster analysis shows that Ycf1p is strongly related to the human multidrug-associated protein (MRP1) and cystic fibrosis transmembrane conductance regulator and therefore may serve as an excellent model for
the study of eukaryotic ABC transporter structure and function.
Identifying intramolecular interactions in these transporters may help
to elucidate energy transfer mechanisms during transport. To identify
regions in Ycf1p that may interact to couple ATPase activity to
substrate binding and/or movement across the membrane, we sought
intragenic suppressors of ycf1 mutations that affect highly conserved residues presumably involved in ATP binding and/or hydrolysis. Thirteen intragenic second-site suppressors were identified for the D777N mutation which affects the invariant Asp residue in the
Walker B motif of the first nucleotide binding domain
(NBD1). Two of the suppressor mutations (V543I and F565L) are located in the first transmembrane domain (TMD1), nine (A1003V, A1021T, A1021V, N1027D, Q1107R, G1207D, G1207S, S1212L, and W1225C) are found within TMD2, one (S674L) is in NBD1, and another one (R1415G) is
in NBD2, indicating either physical proximity or functional interactions between NBD1 and the other three domains. The original D777N mutant protein exhibits a strong defect in the apparent affinity
for ATP and Vmax of transport. The
phenotypic characterization of the suppressor mutants shows that
suppression does not result from restoring these alterations but rather
from a change in substrate specificity. We discuss the possible
involvement of Asp777 in coupling ATPase activity to substrate binding
and/or transport across the membrane.
 |
INTRODUCTION |
The yeast cadmium factor protein
(Ycf1p) is a vacuolar membrane protein involved in heavy metal and drug
detoxification in Saccharomyces cerevisiae. It is an
ATP-dependent pump able to transport organic glutathione S (GS)
conjugates (32), GS-metal complexes (18, 31),
glutathione (41, 42), and other compounds, like
unconjugated bilirubin (39). Ycf1p belongs to the ATP
binding cassette (ABC) superfamily of transporters that includes the
yeast a-factor transporter Ste6p (28), the
Pfmdr-1 of Plasmodium falciparum which is associated with
antimalarial drug resistance (17), and the human proteins
P glycoprotein (16) and multidrug-associated protein
(MRP1) (10) involved in multidrug resistance or the cystic
fibrosis transmembrane conductance regulator, in which mutations cause
cystic fibrosis (44). There are many sequence and
mechanistic similarities between ABC transporters (21,
22), and they have a common evolutionary origin
(11). Structural homology among ABC transporters reflects
functional similarity in some cases, since MRP1 is able to suppress the
Cd2+ hypersensitivity of a yeast
ycf1 mutant (57) and Ycf1p can transport the
physiological substrate of MRP1, the leukotriene LTC4 (15, 43). Ycf1p may thus be an
excellent model for examining structure-function issues relating to
human MRP1 and eukaryotic ABC transporters in general.
Secondary-structure predictions suggest that Ycf1p is formed by two
transmembrane domains (TMDs) and two nucleotide binding domains (NBDs)
(55), as are nearly all members of the ABC superfamily. In
addition, it possesses two subfamily-specific domains: a putative
regulatory domain common to the MRP and cystic fibrosis transmembrane
conductance regulator subfamilies and a third N-terminal TMD
present only in the MRP subfamily (58). The most
characteristic feature of ABC transporters is the NBDs that contain the
highly conserved Walker A (GXXGXGKS/T [X, any amino
acid]), Walker B (Rx6-8
hyd4D) (59), and ABC signature (LSXGXK/R) (25) motifs. Walker A and Walker B are
common to a wide variety of nucleotide binding proteins, whereas the
ABC signature sequence, just upstream of the Walker B motif, is
distinctive to the ABC family. ATP binding and hydrolysis at these
domains are essential for subsequent substrate transport, and ATPase
activity stimulation by substrate binding in several systems has been
demonstrated (12, 34, 50, 54). Coupling of ATPase activity
to substrate binding and transport involves interactions between the
distinct domains of the protein, but the exact nature of the
intramolecular interactions that underlie these effects is not known.
One approach to detecting structural and functional interactions
is to screen for second-site mutations that compensate for a primary
defect in a gene. In this study, we performed an intragenic suppression analysis of five ycf1 mutations located in highly conserved
motifs of the NBDs, all of them involved in binding and/or hydrolysis of ATP (7, 37, 47) and characterized in a previous report (15). We successfully isolated intragenic suppressors for
one of the five mutations, D777N, in the Walker B motif of NBD1. The positions of the suppressors indicate that NBD1 functionally interacts with NBD2 and both TMDs. We discuss the possibility of a direct involvement of Walker B region in coupling ATPase activity and substrate binding and/or transport.
 |
MATERIALS AND METHODS |
Strains, plasmids, and growth media.
A
ycf1
derivative of S. cerevisiae strain W303-1A
(MATa ycf1
::URA3
ade2-1 his3-11,15 leu2-3,112
trp1-1 ura3-1) (15) was used.
Escherichia coli strains XL1-Blue and XL1-Red (mutD5 mutS mutT) (Stratagene) were used for plasmid amplification and mutagenesis, respectively. The centromeric plasmid pRS315
(53) and the episomal plasmid pRS425 (9) were
used for expressing wild-type and mutant YCF1 alleles. In
all cases, YCF1 possessed the nine-amino-acid 12CA5 epitope
sequence from human influenza hemagglutinin (HA) protein immediately
before the termination codon (15). In all experiments,
growth of yeast cells was at 30°C in SD medium (0.7% yeast nitrogen
base without amino acids [US Biological], 2% glucose, pH 5.5)
supplemented with the appropriate auxotrophic requirements (100 µg/ml). SD medium for resistance assays was supplemented with
drop-out mix (BIO 101).
Mutagenesis and selection of revertants
Chemical mutagenesis and propagation of the cloned gene into a mutator
E. coli strain were used to introduce random mutations in the different mutant ycf1 alleles. For chemical
mutagenesis, the plasmid containing the ycf1 allele with
the primary mutation was treated with 0.5 M hydroxylamine and 1 mM
EDTA, pH 6, for 4 h at 70°C. The hydroxylamine was removed by
ethanol precipitation. For in vivo mutagenesis, the plasmid was
transformed into Epicurian E. coli XL1-Red competent
cells by following the manufacturer's instructions (Stratagene). After
growth of transformants for 24 h at 37°C, 2 × 103 to 3 × 103 colonies were picked from
the transformation plates and pooled. Mutated plasmid DNA was isolated
from the pooled transformants and transformed into XL1-Blue strain
cells for DNA amplification. Randomly mutated plasmid DNA obtained by
any of the two procedures was used to transform the yeast
ycf1 strain by using the lithium acetate procedure
(26). Revertants were selected by replica plating onto 50 µM CdCl2 plates for transformants carrying centromeric plasmids or 150 µM CdCl2 plates for those carrying
episomal plasmids. Plasmid DNA was rescued from revertants and
recovered in E. coli cells (46). Yeast
transformation and selection of revertants were repeated with the
recovered plasmid as described above.
Mapping and sequencing of revertant mutants.
To determine
whether the reversion occurred at the site of the original mutation,
the DNA regions that include the primary mutation were sequenced in the
plasmids rescued from revertants of G663V, G756D, and G1306E mutations.
The D777N mutation introduces an MseI restriction
endonuclease site that is absent in the wild-type allele. In this case,
a 0.6-kb DNA fragment was amplified by PCR using plasmid DNA rescued
from revertants as template and subjected to restriction analysis with
MseI. The presence of the primary mutation in the rescued
plasmids would indicate the existence of a second mutation in
YCF1 able to suppress the inactive primary mutation. The
second-site mutations were located within specific YCF1
fragments by single-strand conformation polymorphism analysis of
PCR-amplified fragments (40). Fifteen 0.3- to 0.44-kb
overlapping PCR fragments were generated from each ycf1
suppressor allele so that, when put together, they included DNA
encoding the entire Ycf1p. The PCR mixture contained 5 ng of plasmid
DNA, 10 pmol of each primer, 5 nmol of each of the four
deoxynucleotides, 2.5 mM MgCl2, 1 µCi of
[
-33P]dATP (2,000 Ci/mmol) (10 mCi/ml)
(Amersham), and 2.5 U of Ampli Taq DNA polymerase
(Perkin-Elmer) in 25 µl of the buffer supplied by the manufacturer.
One reaction cycle was performed at 95°C for 3 min, 30 cycles were
performed at at 95, 58, and 72°C for 0.5, 0.5, and 1 min,
respectively, and one cycle was performed at 72°C for 7 min, using a
GeneAmp PCR System 2400 (Perkin-Elmer). Electrophoresis of the PCR
products on nondenaturing 0.35× mutation detection enhancement
(MDE) (FMC BioProducts) gels was performed as previously described
(40), at 6 W in a 4°C cold room for 16 h. The
revertant ycf1 regions corresponding to PCR fragments with
altered mobility were sequenced using fluorescence-labeled dideoxynucleotides in an ABI Prism 377 DNA Sequencer. Once the second-site mutation was identified, a 1.3-kb
BsmI-StuI fragment for V543I, F565L, and S674L
suppressors or a 1.8-kb NdeI-SalI fragment for
the remainder of the suppressors was excised from the revertant and
exchanged with the corresponding fragment in pRS425-ycf1D777N-HA. The
entire restriction fragment exchanged was sequenced to exclude the
possibility of other mutations.
Construction of mutant ycf1 alleles containing
only second-site mutations.
The plasmids containing both the
original D777N and the second-site mutations were digested with
BsmI and NcoI for V543I, F565L, and S674L
suppressors or with NdeI and SalI for the
remaining suppressors. The excised fragments, 1.2 and 1.8 kb,
respectively, were exchanged with the corresponding fragment in
pRS315-YCF1-HA. The resultant plasmids, containing the ycf1
variants with the isolated suppressor mutations, were sequenced to
verify the presence of the second-site mutation and the absence of the
D777N change.
Cadmium and diamide resistance assays.
Qualitative and
quantitative determinations were performed. Cells were cultured for 2 days on SD plates and suspended in water to an optical density at 660 nm (OD660) of 0.4 (2.4 × 107 cells/ml) to be used as inoculum. For
qualitative assays, 5-µl samples were dropped on plates with
CdCl2 or diamide at the indicated concentrations.
Growth was scored after 2 to 3 days of incubation. For quantitative
determination of the MIC, flat-bottom 96-well microtiter plates
containing medium with concentrations ranging from 0 to 1 mM
CdCl2 or 0 to 3 mM diamide were inoculated to a final cell density of 6 × 105 cells/ml.
Inoculum-free wells were also included. The OD595
of each well was determined after a 24-h incubation in the case of diamide or a 2-day incubation in the case of
CdCl2. Data were fitted to a sigmoidal
dose-response equation by using Prism 2.0 GraphPad Software. The MIC is
defined as the lowest concentration at which prominent inhibition of
cell growth (90 to 95%) is observed.
Isolation of vacuolar membrane vesicles.
Intact vacuoles
were isolated by flotation centrifugation of spheroplast lysates on
Ficoll 400 step gradients, as previously described (15).
The resulting vacuole fraction was vesiculated in 5 mM
MgCl2-25 mM KCl-10 mM Tris-MES
(morpholineethanesulfonic acid) (pH 6.9), pelleted by
centrifugation (37,000 × g, 25 min), and resuspended
in buffer (1.1 M glycerol, 2 mM dithiothreitol, 1 mM EGTA, 5 mM
Tris-MES, pH 7.6). All buffers used contained a protease inhibitor
mixture (1 µg of aprotinin/ml, 1 µg of leupeptin/ml, 1 µg of
pepstatin/ml, and 1 mM phenylmethylsulfonyl fluoride).
Measurement of [3H]LTC4 uptake.
Standard uptake experiments were performed at 30°C in TS buffer (250 mM sucrose, 25 mM Tris-MES, pH 8.0) containing 10 mM ATP, 10 mM
MgCl2, 10 mM creatine phosphate, 20 U of creatine
kinase/ml, and 50 nM
[3H]LTC4 (13 nCi/pmol) in
a final volume of 55 µl. Uptake was initiated by addition of vesicles
(1 to 5 µg of protein). LTC4 uptake into vacuolar vesicles increased linearly with the amount of vacuolar membrane protein, at least to 10 µg. Five aliquots (10 µl) were removed at times between 0 and 1.5 min, diluted in 1 ml of ice-cold TS
buffer, immediately filtered through nitrocellulose filters (pore size,
0.45 µm; Millipore) presoaked in TS buffer, and washed twice with 5 ml of ice-cold TS buffer. The retained radioactivity was counted using
liquid scintillation fluid. Initial rates were calculated from the
first 1 min of uptake.
Protein analysis.
Protein concentration was measured by the
Bradford method (8), using the Bio-Rad protein assay
reagent and bovine immunoglobulin G as standard. Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis on 7% gels was performed as
previously described (30). Sample solubilization and
Western blot analysis were performed as previously described (45,
51). Reversible protein staining with Ponceau S (1)
and immunodetection of Ycf1p-HA using mouse anti-HA monoclonal antibody
and a second antibody coupled to alkaline phosphatase (Bio-Rad) was as
previously described (5).
Chemicals.
[3H]LTC4 (165 Ci/mmol)
was obtained from DuPont NEN. Unlabeled LTC4 was
from Sigma. All other reagents were analytical grade and purchased from
Sigma, Roche, Pharmacia, or US Biological.
 |
RESULTS |
Isolation of intragenic suppressors of mutations in NBDs.
For
the intragenic suppressor analysis of mutations localized in the NBDs,
we selected G663V, G756D, D777N, G1306E, and G1311R changes (Fig.
1), all of which affect residues in
highly conserved motifs. Residues Gly663 in NBD1 or Gly1306 and Gly1311
in NBD2 are located in the Walker A motif, which is postulated to form a flexible loop that interacts with bound nucleotide phosphate groups
in the catalytic site of nucleotide-binding proteins (7). Asp777 in the Walker B motif of NBD1 is presumed to play an essential role in Mg2+ binding during ATP hydrolysis
(47). Gly756 is located in the ABC signature motif of
NBD1, which is thought to participate in nucleotide binding and
hydrolysis (37). We previously reported on the effect of
these amino acid replacements on yeast Cd2+
tolerance, Ycf1p biogenesis, and transport activity, showing that all
result in severely impaired Ycf1p-dependent Cd2+
tolerance and transport function without altering the amount of protein
in the vacuolar membrane (15).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Ycf1p mutations chosen for the intragenic suppression
analysis. The amino acid substitutions and their position in the
conserved motifs of Ycf1p NBDs, NBD1 and NBD2, are indicated in a
schematic representation of the predicted topology of an NBD (3,
13, 23, 24, 61). The consensus sequences for Walker A, Walker B,
and ABC signature motifs are indicated. Interactions of bound ATP with
Walker A and Walker B regions are represented by dashed lines.
|
|
Centromeric or episomal plasmids carrying each of the five
ycf1 mutant alleles selected for suppression analysis were
mutagenized
in vitro with hydroxylamine or in vivo by
propagating the plasmids
into a mutator
E. coli
strain as described in Materials and Methods
(summarized in Table
1). The mutagenized plasmids were
introduced
into the
ycf1 strain, and transformants were
screened for growth
on Cd
2+ plates. Mutagenesis
of plasmids containing the G663V, G756D,
D777N, and G1306E mutations
resulted in transformants that grew
in the presence of
Cd
2+, whereas mutagenesis of a plasmid containing
the
G1311R allele
did not (Table
1). To disprove that
mutations in the yeast genome
could contribute to the
Cd
2+-tolerant phenotype, plasmids of revertants
were rescued and reintroduced
into
ycf1 cells to
ascertain their activity. The isolated plasmids
were then tested for
retention of the original substitutions as
described in Materials and
Methods. All revertants of G663V, G756D,
and G1306E mutants were full
revertants of the initial mutation,
and 30 out of 83 revertants
isolated for the D777N mutant were
due to a second-site suppressor
mutation.
Mapping and sequencing of suppressors of D777N mutant.
The
suppressing mutations were mapped by single-strand conformation
polymorphism (see Materials and Methods). Once the region bearing the
intragenic suppressor mutation had been narrowed down to 300 to 450 bp,
it was sequenced. The DNA sequence changes and predicted amino acid
alterations are shown in Table 2. To test whether or not the mutations identified were sufficient to confer Cd2+ tolerance, all changes were reconstructed
into the original ycf1D777N by exchange of different
restriction fragments (see Materials and Methods). In those cases in
which two amino acid changes were found, the mutation responsible for
the restoration of Cd2+ tolerance was identified
by subcloning the mutations separately. Identification of the
mutational changes in the suppressing alleles revealed 13 different
amino acid changes that suppress D777N mutation. In each case, the
change identified was sufficient to confer suppression. Certain
mutations were detected more than once; these included A1021V
(four times), A1021T (three), G1207D (two), G1207S (two), and W1225C
(seven). In these cases, identification of the same nucleotide
substitution in independent clones suggests that these mutations
emerged from amplification of a single mutagenic event during growth of
the mutator strain. Nevertheless, the fact that A1021 and G1207
residues were targeted more than once but with different amino
acids each time and that two distinct codons were found for the W1225C
substitution indicates that these mutations arose from independent
mutagenic events and suggests that these residues may play an important
role in suppressing the defect of the D777N mutant. The second-site
mutations mapped to four different domains of Ycf1p (Fig.
2). Two mutations (V543I and F565L) were
localized in TMD1, nine substitutions (A1003V, A1021T, A1021V,
N1027D, Q1107R, G1207D, G1207S, S1212L, and W1225C) were found within
TMD2, one mutation (S674L) was localized in NBD1, and another
(R1415G) was in NBD2.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 2.
Location of the suppressor mutations found in revertants
of the D777N mutant. The positions of the amino acid substitutions are
included in the predicted model for the domain structure of Ycf1p based
on the structural model that was previously proposed (58).
In the additional TMD0 domain, four TM segments have been represented,
but it is predicted to contain four to six segments. The highly
conserved regions of the NBDs, Walker A, ABC signature, and Walker B,
are indicated, as well as the position of the original D777N
mutation.
|
|
Next, we characterized several aspects of Ycf1p function in the
revertants from the D777N mutant. This characterization included
the
capacity to confer resistance to different toxic substrates
in vivo,
the protein expression level, and the transport capacity
in vacuolar
membrane
vesicles.
Phenotypic characterization of revertants from D777N mutant.
The ability of the second-site mutations to suppress the
Cd2+ sensitivity of the D777N mutant was tested
on plates containing 100 or 300 µM CdCl2 and
further quantified by determining the MICs of the compound for these
mutants (Fig. 3). Only
one of these mutants, bearing a Trp1225-to-Cys change as well as the
original change, was considerably more active than the wild type. The
remaining mutants showed partial restoration of
Cd2+ tolerance to various degrees. Ycf1p is also
involved in tolerance to diamide, an oxidative stress agent
(60). To determine whether the suppressor mutations
affected Ycf1p-dependent resistance to other toxic substrates, we
examined growth on diamide of the suppressed mutants in comparison with
the wild type and D777N mutant.
ycf1 and D777N mutant
strains were hypersensitive to diamide relative to the resistance shown
by the wild-type strain (Fig. 3). The majority of the suppressor
mutations improved to different extents the growth on diamide of the
D777N mutant. Although the original mutant failed to grow on 1.5 mM
diamide, 11 suppressed mutants grew at this concentration, of which 5 grew at an even higher concentration (V543I, F565L, Q1107R, G1207D,
G1207S). On the contrary, mutations W1225C and R1415G did not restore
the growth defect of the D777N mutant on diamide. In a detailed
comparison of the ability to grow on Cd2+ and
diamide for each of the suppressors, a lack of correlation was apparent
between the increase in Cd2+ tolerance and the
correction of the defect on diamide. Suppressor W1225C not only
restored the growth defect of the D777N mutant but, as mentioned above,
produced a gain-of-function phenotype for Cd2+
resistance, whereas it was completely unable to grow on 1.5 mM diamide.
The mutant R1415G did not grow at all on diamide but showed a nearly
twofold increase in its ability to grow on Cd2+
compared to the mutant D777N. On the other hand, among the group of
mutants that corrected the Cd2+ defect to a
similar extent (V543I, F565L, A1003V, A1021T, A1021V, Q1107R, G1207D,
G1207S, and S1212L), only five (V543I, F565L, Q1107R, G1207D, and
G1207S) were able to grow on 2 mM diamide (Fig. 3). These data indicate
a change in the substrate specificity of some of the suppressors.

View larger version (65K):
[in this window]
[in a new window]
|
FIG. 3.
Resistance profile of the revertants of the D777N
mutant. Cells of yeast strain ycf1 were transformed
with the episomal plasmid pRS425 ( ycf1),
pRS425-YCF1-HA (wild type), or pRS425-ycf1-HA (revertant listed) and
grown on SD plates. Drops of each diluted strain (see Materials and
Methods) were placed onto SD drop-out plates containing the indicated
CdCl2 or diamide concentrations, grown for 48 h
(diamide) or 72 h (CdCl2) at 30°C, and photographed.
For quantitative determination of CdCl2 and diamide
tolerance, MIC measurement was performed as described (see Materials
and Methods) after growth of each strain at 30°C on microtiter plates
containing medium with different concentrations of the compounds.
Values are the means of independent duplicate experiments.
|
|
To determine whether the increased growth capacity on
Cd
2+ or diamide of the suppressors was due to an
increment in the amount
of the mutant protein, the relative amount of
Ycf1p in the vacuolar
membrane of the suppressor strains was estimated
by immunoassay.
The mutant proteins were expressed at similar levels,
or at least
not higher, when compared with the expression of the
wild-type
and D777N controls (Fig.
4A).
As expected, no Ycf1p was detectable
in the
ycf1 strain
transformed with the empty vector. Similar
results were obtained in
total membranes (data not shown). These
results indicate that the
greater resistance of the suppressors
is not due to an increase of
mutant Ycf1p in the vacuolar membrane.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 4.
Expression levels of wild-type and mutant Ycf1p in yeast
vacuolar membranes. (A) Vacuolar membrane vesicles of the
ycf1 strain transformed with pRS425
( ycf1), pRS425-YCF1-HA (wild type), or related
plasmids encoding each of the revertant mutant enzymes were isolated as
described (see Materials and Methods), subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (2.5 µg of protein/lane),
and immunodetected with an anti-HA monoclonal antibody and a second
antibody coupled to alkaline phosphatase. (B) Vacuolar membrane
vesicles of the ycf1 strain transformed with pRS315
( ycf1), pRS315-YCF1-HA (wild type), or related
plasmids encoding each of the isolated suppressor mutant enzymes were
prepared, electrophoresed (4 µg of protein/lane), and immunodetected
as described for panel A.
|
|
To shed some light on the suppression mechanism of the mutants, the
kinetic parameters of LTC
4 transport were
determined in
vacuolar membrane vesicles from each revertant. As
mentioned above,
Asp777 is proposed to be the residue that interacts
with magnesium
ion during ATP hydrolysis (
24,
47).
Accordingly, D777N mutant
protein exhibits a strong defect in the
apparent affinity for
ATP and maximal activity of
LTC
4 transport (
15). These defects
in the kinetic parameters of the transporter could be the basis
for its
low tolerance to different Ycf1p transport substrates
in vivo. The
suppressor alleles provide a tool to test this proposal.
In the case of
the W1225C suppressor mutation, these kinetic parameters
could not be
determined since this mutant exhibited no detectable
transport activity
for LTC
4. Table
3
shows that, contrary to
what might be expected, none of the mutants
showed significant
changes in the apparent affinity for ATP, and minor
increases
in the
Vmax compared with
that of D777N were detected in only
three cases. Two of the suppressors
even showed a decrease in
the maximal activity. The majority of the
mutants had 68 to 120%
of the maximal activity of the D777N mutant
enzyme. The highest
activity was observed in mutants N1027D (147%) and
G1207S (138%),
whereas mutants F565L (33%) and G1207D (47%) had the
lowest. These
data suggest that neither the low affinity for ATP nor
the
Vmax defect, as measured with
LTC
4, of the D777N mutant is the primary
defect
responsible for the inability of this mutant protein to
support cell
growth in the presence of metal ions or other toxins.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Effect of the D777N suppressor mutations on the kinetic
parameters of LTC4 uptake in vacuolar membrane vesicles
|
|
Generation and phenotypic characterization of mutants
containing only secondary mutations.
One way to get further
information is the study of the mutants carrying ycf1
alleles with the second-site mutation alone. If the substituted amino
acid forms a critical interaction with another residue, it might be
expected that mutagenesis of this residue in an otherwise wild-type
background would yield a defective phenotype. For this reason, we
separated the suppressors from the original D777N mutation and tested
their properties by analyzing their expression level and their ability
to grow on plates containing CdCl2 or diamide and
determining the MICs of these substrates. The mutants expressed Ycf1p
at wild-type levels (Fig. 4B), but only three of them, S674L, A1003V,
and N1027D, showed a wild-type phenotype when their sensitivity to
Cd2+ and diamide was tested (Fig.
5). The resistance phenotypes of cells
expressing the remaining 10 suppressor mutations could be grouped
according to their different phenotypes. First, mutants A1021T, A1021V,
G1207D, S1212L, and R1415G were more sensitive than the wild-type
strain to inhibition by both Cd2+ and diamide,
with 35 to 80% decreases in the MICs of these substrates when compared
to those for the wild type. Second, mutants V543I, F565L, and Q1107R
grew on diamide medium as much as the wild-type control, whereas growth
on Cd2+ was clearly reduced (MICs ranging from 37 to 60% of that for the control). Third, mutant G1207S displayed a
Cd2+ resistance similar to that of the wild-type
cells but an enhanced tolerance to diamide. Finally, cells with mutant
W1225C Ycf1p tolerated a Cd2+ concentration
ninefold higher than the wild-type cells did, but their growth on
diamide-containing medium was indistinguishable from that of the
ycf1 strain. Thus, the resistance phenotype analysis of the second-site mutants showed a group of
nonfunctional mutants for both substrates, A1021T, A1021V,
G1207D, S1212L, and R1415G, indicating that Ala1021, Glu1207,
Ser1212, and Arg1415 are functionally important residues in Ycf1p. In
addition, it revealed a group of suppressor mutants, V543I, F565L,
Q1107R, G1207S, and W1225C, with a switch in their resistance profile indicating that Val543, Phe565, Gln1107, Gly1207, and Trp1225 are
involved in determination of substrate specificity.

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 5.
Resistance profile of the second-site mutants. Cells of
the ycf1 yeast strain were transformed with the
centromeric plasmid pRS315 ( ycf1), pRS315-YCF1-HA
(wild type), or pRS315-ycf1-HA (revertant listed) and grown on SD
plates. Drops of each diluted strain (see Materials and Methods) were
placed onto SD drop-out plates containing the indicated
CdCl2 or diamide concentrations, grown for 48 h
(diamide) or 72 h (CdCl2) at 30°C, and photographed.
For quantitative determination of CdCl2 and diamide
tolerance, MIC measurement was performed as described (see Materials
and Methods) after growth of each strain at 30°C on microtiter plates
containing medium with different concentrations of the compounds.
Values are the mean of independent duplicate experiments.
|
|
 |
DISCUSSION |
Existing models for the transport cycle of ABC transporters
suggest a close interaction between the NBDs and the TMDs.
Nevertheless, the precise mechanism of signaling after substrate
binding from the TMDs to the NBDs for stimulation of ATP hydrolysis
remains poorly understood. In the same way, the mechanism by which ATP hydrolysis at the NBDs causes a structural change in the protein, presumably in the TMDs, to originate substrate transport across the
membrane is unknown. This study was designed to gain insight into these
problems and to identify interacting regions of the protein that could
potentially be involved in the conformational changes produced in the
catalytic sites during the transport cycle.
We performed a revertant analysis of five mutations located in
the NBDs of Ycf1p, namely G663V, G756D, D777N, G1306E, and G1311R. The
altered residues are completely conserved among ABC transporters and
apparently involved in ATP binding and/or hydrolysis, as they are
located in the Walker A, Walker B, and ABC signature motifs
(48). Using this genetic approach, we isolated 13 different second-site mutations that suppress, to various degrees, the
high sensitivity of the D777N mutant to Cd2+ and diamide.
We were unable to identify any intragenic suppressors of the other four
alleles, G663V, G756D, G1306E, and G1311R. There are a number of
reasons that suppressor mutations may have gone undetected, including a
limited number of transformants screened, or mutagenesis that was not
entirely random due to mutational hot spots and specificity of the
mutagenic agent used. We used a combination of mutagenesis procedures
and tested a large number of transformants. One of the mutagenic
protocols, the use of a mutator strain of E. coli, is
described as largely unbiased (19). On the basis of these observations and of the isolation, for the D777N mutant, of independent suppressor mutations in 13 residues, we believe that there is a severe
limitation on the number of single-amino-acid alterations that will
suppress these mutations. Moreover, the NBD1 mutations G663V and G756D
were not suppressed when combined with some of the suppressors isolated
for D777N (see below). Intragenic suppressors of four mutations located
in the Walker A motif in the
-subunit of the yeast mitochondrial
ATPase have been sought (52). The lack of suppressors for
one mutation and the identification of only one suppressor for each of
the other three in that study also argues in favor of our interpretation.
The suppressors isolated for the D777N mutant are located in four
domains: TMD1, TMD2, NBD1, and NBD2. The location of second-site revertants within TMD1, TMD2, and NBD2 supports the structural and/or
functional interaction between these domains and NBD1.
Eleven of the 13 suppressors isolated are located in the TMDs, not only
in the predicted intracytoplasmic loops (A1021T, A1021V, and N1027D)
but included in the membrane (V543I, F565L, A1003V, Q1107R, S1212L, and
W1225C) or even facing the vacuolar lumen (G1207D and G1207S). This
localization suggests intimate interaction between NBD1 and both TMDs.
This is in agreement with present structural models that are based on
studies on several ABC transporters in which NBD accessibility to
proteases and biotinylated reagents from both sides of the membrane was
investigated (4, 6, 20, 49). These models propose that
part of the NBDs may span the lipid bilayer and be exposed to the
noncytoplasmic surface through the pore formed by the TMDs.
Currently, based on the crystal structure of the ATPase subunits of
several ABC transporters, two conflicting models for the dimeric
arrangement of the NBDs are emerging. One of these models proposes that
the two nucleotide binding sites are facing away from each other
(24). In the second, the ABC signature motif of one NBD
completes the ATP binding site (Walker A and B motifs) of the other
(3, 23, 27, 61). In the case of Ycf1p, it is noteworthy
that one of the second-site D777N suppressor mutations, R1415G, affects
a highly conserved Arg residue in the ABC signature motif of NBD2,
suggesting a model in which interaction of the two NBDs occurs.
To unravel the mechanism by which the suppressor mutations might act,
they were studied in isolation. The results show that a significant
fraction of the suppressors,V543I, F565L, A1021T, A1021V, Q1107R,
G1207D, S1212L, and R1415G, are deficient for Ycf1p function in cadmium
detoxification, pointing to a specific suppression mechanism. The
specificity of the suppression is further supported by the fact that
neither the W1225C nor R1415G mutations were able to suppress the
defective growth or Ycf1p transport function of the other NBD1 primary
mutations, namely G663V and G756D (data not shown). These results
suggest that the suppressor mutations do not suppress by bypassing the
function of Asp777 in Ycf1p and rather indicate that the Val543,
Phe565, Ala1021, Gln1107, Gly1207, Ser1212, and Arg1415 residues are
involved in intramolecular interactions that are relevant for the
connection with the Walker B region of the NBD. In contrast, mutations
G1207S and W1225C produce an enhanced Ycf1p function even in the
absence of D777N mutation, indicating a different mechanism of
suppression that involves a change in Ycf1p substrate specificity.
Finally, the suppressor effect of S674L, A1003V, and N1027D mutations
is probably due to nonspecific compensating structural alterations, since these mutations exhibited wild-type behavior in the absence of
the primary mutation.
Phenotypic characterization of the suppressor mutants separated from
the primary mutation showed that five of them, namely V543I, F565L,
Q1107R, G1207S, and W1225C, exhibit individual different responses to
the substrates tested (Fig. 5). This behavior concurs with their
localization in the TMDs. Previous mutational analysis of several ABC
transporters showed that changes introduced into the TMDs (2, 14,
29, 33, 56) can affect substrate specificity. In fact, all of
them map in TM segments for which contribution to specific binding
sites has been documented, namely TM5, TM6, TM10, and TM12 (35,
36, 38). W1225C in TM12 showed a drastic specificity shift. This
mutant appeared to completely disrupt Ycf1p-substrate interactions
except for Cd2+ since no resistance to diamide or
LTC4 transport could be detected. The W1225C
mutant deserves further investigation, since it may provide useful
insights into Ycf1p transport substrate specificity.
The use of suppression genetics to enlighten structure and function
studies is based on the premise that an existing altered function
allele can be restored to wild-type function by a second mutational
change. Thus, by definition, the suppressor mutations reverse the
critical defect of the starting mutant. In addition, the suppressors
can confirm or deny that a property observed in vitro is the critical
one in vivo. The D777N mutant shows in vivo a greatly reduced
resistance to Cd2+, and in vitro kinetic analysis
of the mutant protein revealed that it has an apparently wild-type
Km for LTC4 but
lowered ATP affinity and Vmax for
LTC4 transport (15). The results
presented here show that the suppressor mutants recovered the ability
to grow on Cd2+ whereas none of them restored the
Vmax for LTC4 or
improved the affinity for ATP. On the contrary, some of them share an
alteration in substrate specificity, suggesting that this feature
underlies the suppression mechanism. These findings indicate that the
growth defect of the D777N mutant does not derive from the kinetic
defects detected in vitro. The crucial functional defect may rather be due to another essential function of the Asp777 residue in addition to
ATP binding and/or hydrolysis, such as coupling these processes to
substrate binding and/or transport. The identified second-site mutations could have restored the interactions involving the substrate and ATP binding sites, which are required for transport to occur and
presumably disrupted in the D777N mutant protein. Consistent with this
proposed dual function for the NBD1 invariant Asp residue in the Walker
B region are the results for some of the known NBD structures. In ArsA,
the ATPase subunit of the ArsAB pump of E. coli, two
aspartic residues involved in coordination of
Mg2+ are in close proximity to the allosteric
metal binding site (61) and are proposed to participate in
signal transmission between metal and nucleotide binding sites. In
addition, the high-resolution crystal structure of HisP, the ATPase
subunit of the histidine permease of Salmonella enterica
serovar Typhimurium, places the homologous residue to Asp777 in the
particularly strategic position connecting most residues that contact
ATP with those that may interact with the TM subunits
(24). The location and phenotype of the suppressor
mutations may thus be interpreted if substrate union to its binding
site is directly connected with the NBD1 Walker B region to stimulate
ATPase activity. Further characterization of the suppressor mutants
will allow a deeper understanding of the intramolecular interactions
that are important for Ycf1p transport activity and may be shared by
other ABC transporters.
 |
ACKNOWLEDGMENTS |
This study was supported by Fondo de Investigaciones Sanitarias
Grant 98/1279 and by the Fundación Sira Carrasco para Ayuda a la
Fibrosis Quística.
We thank J. Martín for the anti-HA antibody, F. Portillo for
critical reading of the manuscript and helpful discussions and suggestions, and Eulalia Morgado for technical assistance in some experiments.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Instituto de
Investigaciones Biomédicas "Alberto Sols" CSIC-UAM, Arturo
Duperier 4, 28029 Madrid, Spain. Phone: 34 91 585 4616. Fax: 34 91 585 4587. E-mail: peraso{at}iib.uam.es.
 |
REFERENCES |
| 1.
|
Aebersold, R. H.,
J. Leavitt,
R. A. Saavedra,
L. E. Hood, and S. B. H. Kent.
1987.
Internal amino acid sequence analysis of proteins separated by one- or two-dimensional gel electrophoresis after in situ protease digestion on nitrocellulose.
Proc. Natl. Acad. Sci. USA
84:6970-6974[Abstract/Free Full Text].
|
| 2.
|
Anderson, M. P.,
R. J. Gregory,
S. Thompson,
D. W. Souza,
S. Paul,
R. C. Mulligan,
A. E. Smith, and M. J. Welsh.
1991.
Demonstration that CFTR is a chloride channel by alteration of its anion selectivity.
Science
253:202-205[Abstract/Free Full Text].
|
| 3.
|
Armstrong, S.,
L. Tabernero,
H. Zhang,
M. Hermodson, and C. Stauffacher.
1998.
Powering the ABC transporter: the 2.5 Å crystallographic structure of the ABC domain of RBSA.
Pediatr. Pulmonol.
26:91-92.
|
| 4.
|
Baichwal, V.,
D. Liu, and F. L. Ames.
1993.
The ATP-binding component of a prokaryotic traffic ATPase is exposed to the periplasmic (external) surface.
Proc. Natl. Acad. Sci. USA
90:620-624[Abstract/Free Full Text].
|
| 5.
|
Blake, M. S.,
K. H. Johnston,
G. H. Russell-Jones, and E. C. Gotschlich.
1984.
A rapid, sensitive method for detection of alkaline phosphatase-conjugated anti-antibody on Western blots.
Anal. Biochem.
136:175-179[CrossRef][Medline].
|
| 6.
|
Bliss, J. M., and P. S. Silver.
1997.
Evidence that KpsT, the ATP-binding component of an ATP-binding cassette transporter, is exposed to the periplasm and associates with polymer during translocation of the polysialic acid capsule of Escherichia coli K1.
J. Bacteriol.
179:1400-1403[Abstract/Free Full Text].
|
| 7.
|
Bourne, H. R.,
D. A. Sanders, and F. McCormick.
1991.
The GTPase superfamily: conserved structure and molecular mechanism.
Nature
349:117-127[CrossRef][Medline].
|
| 8.
|
Bradford, M. M.
1976.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem.
72:248-254[CrossRef][Medline].
|
| 9.
|
Christianson, T. W.,
R. S. Sikorski,
M. Dante,
J. H. Shero, and P. Hieter.
1992.
Multifunctional yeast high-copy-number shuttle vectors.
Gene
110:119-122[CrossRef][Medline].
|
| 10.
|
Cole, S. P. C.,
G. Bhardwaj,
J. H. Gerlach,
J. E. Mackie,
C. E. Grant,
K. C. Almquist,
A. J. Stewart,
E. U. Kurz,
A. M. V. Duncan, and R. G. Deeley.
1992.
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.
Science
258:1650-1654[Abstract/Free Full Text].
|
| 11.
|
Croop, J. M.
1998.
Evolutionary relationships among ABC transporters.
Methods Enzymol.
292:101-116[CrossRef][Medline].
|
| 12.
|
Davidson, A. L.,
H. A. Shuman, and H. Nikaido.
1992.
Mechanism of maltose transport in Escherichia coli: transmembrane signaling by periplasmic binding proteins.
Proc. Natl. Acad. Sci. USA
89:2360-2364[Abstract/Free Full Text].
|
| 13.
|
Diederichs, K.,
J. Diez,
G. Greller,
C. Müller,
J. Breed,
C. Schnell,
C. Vonrhein,
W. Boos, and W. Welte.
2000.
Crystal structure of MalK, the ATPase subunit of the trehalose/maltose ABC transporter of the archaeon Thermococcus litoralis.
EMBO J.
19:5951-5961[CrossRef][Medline].
|
| 14.
|
Egner, R.,
F. E. Rosenthal,
A. Kralli,
D. Sanglard, and K. Kuchler.
1998.
Genetic separation of FK506 susceptibility and drug transport in the yeast Pdr5 ATP-binding cassette multidrug resistance transporter.
Mol. Biol. Cell
9:523-543[Abstract/Free Full Text].
|
| 15.
|
Falcón-Pérez, J. M.,
M. J. Mazón,
J. Molano, and P. Eraso.
1999.
Functional domain analysis of the yeast ABC transporter Ycf1p by site-directed mutagenesis.
J. Biol. Chem.
274:23584-23590[Abstract/Free Full Text].
|
| 16.
|
Fojo, A. T.,
J. Whang-Peng,
M. M. Gottesman, and I. Pastan.
1985.
Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells.
Proc. Natl. Acad. Sci. USA
82:7661-7665[Abstract/Free Full Text].
|
| 17.
|
Foote, S. J.,
J. K. Thompson,
A. F. Cowman, and D. J. Kemp.
1989.
Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum.
Cell
57:921-930[CrossRef][Medline].
|
| 18.
|
Ghosh, M.,
J. Shen, and B. P. Rosen.
1999.
Pathways of As(III) detoxification in Saccharomyces cerevisiae.
Proc. Natl. Acad. Sci. USA
96:5001-5006[Abstract/Free Full Text].
|
| 19.
|
Greener, A., and M. Callahan.
1994.
XL1-Red: a highly efficient random mutagenesis strain.
Strategies
7:32-34.
|
| 20.
|
Gruis, D. B., and E. M. Price.
1997.
The nucleotide binding folds of the cystic fibrosis transmembrane conductance regulator are extracellularly accessible.
Biochemistry
36:7739-7745[CrossRef][Medline].
|
| 21.
|
Higgins, C. F.
1992.
ABC transporters: from microorganisms to man.
Annu. Rev. Cell Biol.
8:67-113[CrossRef].
|
| 22.
|
Holland, I. B., and M. A. Blight.
1999.
ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans.
J. Mol. Biol.
293:381-399[CrossRef][Medline].
|
| 23.
|
Hopfner, K.-P.,
A. Karcher,
D. S. Shin,
L. Craig,
L. M. Arthur,
J. P. Carney, and J. A. Tainer.
2000.
Structural biology of Rad50 ATPase: ATP-driven conformational control in DNA double-strand break repair and the ABC-ATPase superfamily.
Cell
101:789-800[CrossRef][Medline].
|
| 24.
|
Hung, L.-W.,
I. X. Wang,
K. Nikaido,
P.-Q. Liu,
G. F.-L. Ames, and S.-H. Kim.
1998.
Crystal structure of the ATP-binding subunit of an ABC transporter.
Nature
396:703-707[CrossRef][Medline].
|
| 25.
|
Hyde, S. C.,
P. Emsley,
M. J. Hartshorn,
M. M. Mimmack,
U. Gileadi,
S. R. Pearce,
M. P. Gallagher,
D. R. Gill,
R. E. Hubbard, and C. F. Higgins.
1990.
Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport.
Nature
346:362-365[CrossRef][Medline].
|
| 26.
|
Ito, H.,
Y. Fukuda,
K. Murata, and A. Kimura.
1983.
Transformation of intact yeast cells treated with alkali cations.
J. Bacteriol.
153:163-168[Abstract/Free Full Text].
|
| 27.
|
Jones, P. M., and A. M. George.
1999.
Subunit interactions in ABC transporters: towards a functional architecture.
FEMS Microbiol. Lett.
179:187-202[CrossRef][Medline].
|
| 28.
|
Kuchler, K.,
R. E. Sterne, and J. Thorner.
1989.
Saccharomyces cerevisiae STE6 gene product: a novel pathway for protein export in eukaryotic cells.
EMBO J.
8:3973-3984[Medline].
|
| 29.
|
Kwan, T., and P. Gros.
1998.
Mutational analysis of the P-glycoprotein first intracellular loop and flanking transmembrane domains.
Biochemistry
37:3337-3350[CrossRef][Medline].
|
| 30.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 31.
|
Li, Z.-S.,
Y.-P. Lu,
R.-G. Zhen,
M. Szczypka,
D. J. Thiele, and P. A. Rea.
1997.
A new pathway for vacuolar cadmium sequestration in Saccharomyces cerevisiae: YCF1-catalyzed transport of bis(glutathionato)cadmium.
Proc. Natl. Acad. Sci. USA
94:42-47[Abstract/Free Full Text].
|
| 32.
|
Li, Z.-S.,
M. Szczypka,
Y.-P. Lu,
D. J. Thiele, and P. A. Rea.
1996.
The yeast cadmium factor protein (YCF1) is a vacuolar glutathione S-conjugate pump.
J. Biol. Chem.
271:6509-6517[Abstract/Free Full Text].
|
| 33.
|
Linsdell, P.,
A. Evagelidis, and J. W. Hanrahan.
2000.
Molecular determinants of anion selectivity in the cystic fibrosis transmembrane conductance regulator chloride channel pore.
Biophys. J.
78:2973-2982[Medline].
|
| 34.
|
Liu, C. E.,
P.-Q. Liu, and G. F.-L. Ames.
1997.
Characterization of the adenosine triphosphatase activity of the periplasmic histidine permease, a traffic ATPase (ABC transporter).
J. Biol. Chem.
272:21883-21891[Abstract/Free Full Text].
|
| 35.
|
Loo, T. W., and D. M. Clarke.
1997.
Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate.
J. Biol. Chem.
272:31945-31948[Abstract/Free Full Text].
|
| 36.
|
Loo, T. W., and D. M. Clarke.
2001.
Defining the drug-binding site in the human multidrug resistance P-glycoprotein using methanethiosulfonate analog of verapamil, MTS-verapamil.
J. Biol. Chem.
276:14972-14979[Abstract/Free Full Text].
|
| 37.
|
Manavalan, P.,
D. G. Dearborn,
J. M. McPherson, and A. E. Smith.
1995.
Sequence homologies between nucleotide binding regions of CFTR and G-proteins suggest structural and functional similarities.
FEBS Lett.
366:87-91[CrossRef][Medline].
|
| 38.
|
Morris, D. I.,
L. M. Greenberger,
E. P. Bruggemann,
C. Cardarelli,
M. M. Gottesman,
I. Pastan, and K. B. Seamon.
1994.
Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin.
Mol. Pharmacol.
46:329-337[Abstract].
|
| 39.
|
Petrovic, S.,
L. Pascolo,
R. Gallo,
F. Cupelli,
J. D. Ostrow,
A. Goffeau,
C. Tiribelli, and C. V. Bruschi.
2000.
The products of YCF1 and YLL015w (BPT1) cooperate for the ATP-dependent vacuolar transport of unconjugated bilirubin in Saccharomyces cerevisiae.
Yeast
16:561-571[CrossRef][Medline].
|
| 40.
|
Ravnik-Glavac, M.,
D. Glavac, and M. Dean.
1994.
Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic fibrosis gene.
Hum. Mol. Genet.
3:801-807[Abstract/Free Full Text].
|
| 41.
|
Rebbeor, J. F.,
G. C. Connolly,
M. E. Dumont, and N. Ballatori.
1998.
ATP-dependent transport of reduced glutathione in yeast secretory vesicles.
Biochem. J.
334:723-729.
|
| 42.
|
Rebbeor, J. F.,
G. C. Connolly,
M. E. Dumont, and N. Ballatori.
1998.
ATP-dependent transport of reduced glutathione on YCF1, the yeast orthologue of mammalian multidrug resistance associated proteins.
J. Biol. Chem.
273:33449-33454[Abstract/Free Full Text].
|
| 43.
|
Ren, X.-Q.,
T. Furukawa,
Z.-S. Chen,
H. Okumura,
S. Aoki,
T. Sumizawa,
A. Tani,
M. Komatsu,
X.-D. Mei, and S. Akiyama.
2000.
Functional comparison between YCF1 and MRP1 expressed in Sf21 insect cells.
Biochem. Biophys. Res. Commun.
270:608-615[CrossRef][Medline].
|
| 44.
|
Riordan, J. R.,
J. M. Rommens,
B.-S. Kerem,
N. Alon,
R. Rozmahel,
Z. Grzelczak,
J. Zielenski,
S. Lok,
N. Plavsic,
J.-L. Chou,
M. L. Drumm,
M. C. Iannuzzi,
F. S. Collins, and L.-C. Tsui.
1989.
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.
Science
245:1066-1073[Abstract/Free Full Text].
|
| 45.
|
Romero, I.,
A. M. Maldonado, and P. Eraso.
1997.
Glucose-independent inhibition of yeast plasma-membrane H+-ATPase by calmodulin antagonists.
Biochem. J.
322:823-828.
|
| 46.
|
Rose, M. D.,
F. Winston, and P. Hieter (ed.).
1990.
Methods in yeast genetics. A laboratory course manual, p. 128-129.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 47.
|
Schlichting, I.,
S. C. Almo,
G. Rapp,
K. Wilson,
K. Petratos,
A. Lentfer,
A. Wittinghofer,
W. Kabsch,
E. F. Pai,
G. A. Petsko, and R. S. Goody.
1990.
Time-resolved X-ray crystallographic study of the conformational change in Ha-Ras p21 protein on GTP hydrolysis.
Nature
345:309-315[CrossRef][Medline].
|
| 48.
|
Schneider, E., and S. Hunke.
1998.
ATP-binding-cassette (ABC) transport systems: functional and structural aspects of the ATP-hydrolyzing subunits/domains.
FEMS Microbiol. Rev.
22:1-20[CrossRef][Medline].
|
| 49.
|
Schneider, E.,
S. Hunke, and S. Tebbe.
1995.
The MalK protein of the ATP-binding cassette transporter for maltose of Escherichia coli is accessible to protease digestion from the periplasmic side of the membrane.
J. Bacteriol.
177:5364-5367[Abstract/Free Full Text].
|
| 50.
|
Senior, A. E.,
M. K. Al-Shawi, and I. L. Urbatsch.
1995.
ATP hydrolysis by multidrug-resistance protein from Chinese hamster ovary cells.
J. Bioenerg. Biomembr.
27:31-36[CrossRef][Medline].
|
| 51.
|
Serrano, R.,
C. Montesinos,
M. Roldán,
G. Garrido,
C. Ferguson,
K. Leonard,
B. C. Monk,
D. S. Perlin, and E. W. Weiler.
1991.
Domains of yeast plasma membrane and ATPase-associated glycoprotein.
Biochim. Biophys. Acta
1062:157-164[Medline].
|
| 52.
|
Shen, H.,
A. Sosa-Peinado, and D. M. Mueller.
1996.
Intragenic suppressors of P-loop mutations in the -subunit of the mitochondrial ATPase in the yeast Saccharomyces cerevisiae.
J. Biol. Chem.
271:11844-11851[Abstract/Free Full Text].
|
| 53.
|
Sikorski, R. S., and P. Hieter.
1989.
A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae.
Genetics
122:19-27[Abstract/Free Full Text].
|
| 54.
|
Sun, H.,
R. S. Molday, and J. Nathans.
1999.
Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease.
J. Biol. Chem.
274:8269-8281[Abstract/Free Full Text].
|
| 55.
|
Szczypka, M. S.,
J. A. Wemmie,
W. S. Moye-Rowley, and D. J. Thiele.
1994.
A yeast metal resistance protein similar to human cystic fibrosis transmembrane conductance regulator (CFTR) and multidrug resistance-associated protein.
J. Biol. Chem.
269:22853-22857[Abstract/Free Full Text].
|
| 56.
|
Taguchi, Y.,
K. Kino,
M. Morishima,
T. Komano,
S. E. Kane, and K. Ueda.
1997.
Alteration of substrate specificity by mutations at the His61 position in predicted transmembrane domain 1 of human MDR1/P-glycoprotein.
Biochemistry
36:8883-8889[CrossRef][Medline].
|
| 57.
|
Tommasini, R.,
R. Evers,
E. Vogt,
C. Mornet,
G. J. Zaman,
A. H. Schinkel,
P. Borst, and E. Martinoia.
1996.
The human multidrug resistance-associated protein functionally complements the yeast cadmium resistance factor 1.
Proc. Natl. Acad. Sci. USA
93:6743-6748[Abstract/Free Full Text].
|
| 58.
|
Tusnády, G. E.,
E. Bakos,
A. Váradi, and B. Sarkadi.
1997.
Membrane topology distinguishes a subfamily of the ATP-binding cassette (ABC) transporters.
FEBS Lett.
402:1-3[CrossRef][Medline].
|
| 59.
|
Walker, J. E.,
M. Saraste,
M. J. Runswick, and N. J. Gay.
1982.
Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold.
EMBO J.
1:945-951[Medline].
|
| 60.
|
Wemmie, J. A., and W. S. Moye-Rowley.
1997.
Mutational analysis of the Saccharomyces cerevisiae ATP-binding cassette transporter protein Ycf1p.
Mol. Microbiol.
25:683-694[CrossRef][Medline].
|
| 61.
|
Zhou, T.,
S. Radaev,
B. P. Rosen, and D. L. Gatti.
2000.
Structure of the ArsA ATPase: the catalytic subunit of a heavy metal resistance pump.
EMBO J.
19:4838-4845[CrossRef][Medline].
|
Journal of Bacteriology, August 2001, p. 4761-4770, Vol. 183, No. 16
0021-9193/01/$04.00+0 DOI: 10.1128/JB.183.16.4761-4770.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kaur, J., Bachhawat, A. K.
(2009). Gln-222 in Transmembrane Domain 4 and Gln-526 in Transmembrane Domain 9 Are Critical for Substrate Recognition in the Yeast High Affinity Glutathione Transporter, Hgt1p. J. Biol. Chem.
284: 23872-23884
[Abstract]
[Full Text]
-
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., Monk, B. C.
(2009). Efflux-Mediated Antifungal Drug Resistance. Clin. Microbiol. Rev.
22: 291-321
[Abstract]
[Full Text]
-
Du, K., Lukacs, G. L.
(2009). Cooperative Assembly and Misfolding of CFTR Domains In Vivo. Mol. Biol. Cell
20: 1903-1915
[Abstract]
[Full Text]
-
Mason, D. L., Mallampalli, M. P., Huyer, G., Michaelis, S.
(2003). A Region within a Lumenal Loop of Saccharomyces cerevisiae Ycf1p Directs Proteolytic Processing and Substrate Specificity. Eukaryot Cell
2: 588-598
[Abstract]
[Full Text]
-
Mason, D. L., Michaelis, S.
(2002). Requirement of the N-Terminal Extension for Vacuolar Trafficking and Transport Activity of Yeast Ycf1p, an ATP-binding Cassette Transporter. Mol. Biol. Cell
13: 4443-4455
[Abstract]
[Full Text]
-
deCarvalho, A. C. V., Gansheroff, L. J., Teem, J. L.
(2002). Mutations in the Nucleotide Binding Domain 1 Signature Motif Region Rescue Processing and Functional Defects of Cystic Fibrosis Transmembrane Conductance Regulator Delta F508. J. Biol. Chem.
277: 35896-35905
[Abstract]
[Full Text]